PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.79%
Revenue growth at 50-75% of CRON.TO's 27.57%. Martin Whitman would worry about competitiveness or product relevance.
-55.89%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-110.68%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-110.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-140.68%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-129.18%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-128.65%
Negative diluted EPS growth while CRON.TO is at 4.78%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
40.06%
Share count expansion well above CRON.TO's 23.36%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
37.54%
Diluted share count expanding well above CRON.TO's 52.74%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-4001.79%
Negative OCF growth while CRON.TO is at 290.13%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
29.11%
FCF growth under 50% of CRON.TO's 73.08%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
428.38%
3Y CAGR of 428.38% while CRON.TO is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
-2160.23%
Negative 10Y OCF/share CAGR while CRON.TO stands at 1185.74%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-519.63%
Negative 5Y OCF/share CAGR while CRON.TO is at 1185.74%. Joel Greenblatt would question the firm’s operational model or cost structure.
-44.26%
Negative 3Y OCF/share CAGR while CRON.TO stands at 1185.74%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-325.17%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-1884.91%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-128.25%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
4744.30%
10Y equity/share CAGR above 1.5x CRON.TO's 258.45%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5474.80%
5Y equity/share CAGR above 1.5x CRON.TO's 258.45%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
1855.02%
3Y equity/share CAGR above 1.5x CRON.TO's 258.45%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-85.62%
Firm’s AR is declining while CRON.TO shows 76.60%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
86.58%
We show growth while CRON.TO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
52.33%
Asset growth above 1.5x CRON.TO's 5.65%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
11.30%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
-20.34%
We’re deleveraging while CRON.TO stands at 247.20%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
86.76%
R&D growth of 86.76% while CRON.TO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
55.94%
SG&A growth well above CRON.TO's 27.24%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.